This is a StreetInsider.com Premium Only Page

Arbutus Biopharma (ABUS) – StreetInsider.com Reports

Apr 4, 2024 08:35 AM Arbutus Biopharma (ABUS) Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna (MRNA)

Apr 3, 2024 02:02 PM Moderna shares fall after judge sides with Arbutus in patent fight

Apr 3, 2024 01:06 PM Arbutus Biopharma (ABUS) Gains, Moderna (MRNA) Declines Following Order in Patent Case

Jan 8, 2024 07:36 AM Arbutus Biopharma (ABUS) Announces 2024 Corporate Objectives and Provides Financial Update

Nov 7, 2023 07:37 AM Arbutus Biopharma (ABUS) Misses Q3 EPS by 1c

Nov 7, 2023 07:15 AM Arbutus Biopharma (ABUS) Announces CEO, William Collier, to Retire December 31

Sep 12, 2023 07:48 AM Arbutus Biopharma (ABUS) PT Lowered to $4 at JMP Securities

Aug 3, 2023 07:42 AM Arbutus Biopharma (ABUS) Tops Q2 EPS by 1c

Jul 12, 2023 07:32 AM Arbutus Biopharma (ABUS) Appoints Melissa V. Rewolinski to its Board

Jul 10, 2023 04:04 PM Arbutus Biopharma (ABUS) Announces Karen Sims, MD, PhD Promoted to Chief Medical Officer

Apr 27, 2023 05:09 AM Arbutus Biopharma (ABUS) Provides AB-729 Clinical Data and AB-161 Preclinical Data

Apr 25, 2023 07:30 AM Arbutus Biopharma (ABUS) Announces FDA Clinical Hold on IND Application for AB-101

Apr 4, 2023 08:17 AM Arbutus files patent lawsuit against Pfizer/BioNTech over COVID vaccines

Apr 4, 2023 07:53 AM Arbutus Biopharma (ABUS) and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer (PFE) /BioNTech (BNTX)

Mar 28, 2023 08:04 AM Vaccitech plc (VACC) Reports Positive Topline Final Data for HBV002

Mar 16, 2023 07:34 AM Arbutus Biopharma (ABUS) Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161

Mar 14, 2023 04:05 PM Arbutus Biopharma (ABUS) Presents AB-343 Data at the 36th International Conference on Antiviral Research

Mar 2, 2023 07:35 AM Arbutus Biopharma (ABUS) Misses Q4 EPS by 33c

Jan 27, 2023 07:31 AM Arbutus Biopharma (ABUS) Announces Resignation of Tram Tran from Board

Nov 10, 2022 06:48 AM Arbutus Biopharma (ABUS) PT Lowered to $6 at H.C. Wainwright

Nov 9, 2022 07:43 AM Arbutus Biopharma (ABUS) Tops Q3 EPS by 2c

Nov 9, 2022 07:43 AM Arbutus Biopharma (ABUS) Tops Q3 EPS by 2c

Nov 1, 2022 04:03 PM Arbutus Biopharma (ABUS) Presents AB-729 Clinical Data and AB-101 Preclinical Data

Oct 12, 2022 06:40 AM Companies with NDRs 10/12

Aug 30, 2022 07:31 AM Arbutus Biopharma (ABUS) Announces Issuance of New AB-729 Patent

Aug 4, 2022 07:31 AM Arbutus Biopharma (ABUS) Tops Q2 EPS by 2c

Jul 20, 2022 04:11 PM Arbutus Biopharma (ABUS) Announces Assembly Biosciences Discontinues Phase 2A Combination Trial with AB-729

Jun 28, 2022 03:44 AM Arbutus Biopharma (ABUS) PT Lowered to $9 at JMP Securities

Jun 27, 2022 05:59 AM Arbutus Biopharma (ABUS) Presents New Data on AB-729, AB-836 and AB-101

May 26, 2022 05:06 PM Arbutus Biopharma (ABUS) Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 5, 2022 07:33 AM Arbutus Biopharma (ABUS) Tops Q1 EPS by 5c

Mar 22, 2022 04:28 AM Increasing unusual put option volume: SCO BBD IGT WRBY HPQ ABUS

Mar 17, 2022 07:17 AM Companies with NDRs 3/17

Mar 14, 2022 06:18 AM Arbutus Biopharma (ABUS) PT Raised to $8.50 at H.C. Wainwright

Mar 4, 2022 07:27 AM Arbutus Biopharma (ABUS) PT Raised to $6 at Chardan Capital Markets

Feb 28, 2022 09:30 AM Pre-Open Stock Movers 02/28: (MULN) (REGI) (FHN) Higher; (GMBL) (YNDX) (HHR) Lower (more...)

Feb 28, 2022 06:02 AM Arbutus Biopharma (ABUS) and Genevant File Patent Infringement Lawsuit Against Moderna (MRNA)

Feb 2, 2022 09:17 AM Pre-Open Stock Movers 02/02: (CPRI) (AMD) (GOOGL) Higher; (ELMS) (PYPL) (MGNI) Lower (more...)

Feb 2, 2022 02:49 AM Jefferies Upgrades Arbutus Biopharma (ABUS) to Buy

Jan 24, 2022 07:33 AM Arbutus Biopharma (ABUS) Announces 2022 Corporate Objectives and Provides Financial Update

Dec 29, 2021 03:51 AM UPDATE: Jefferies Assumes Arbutus Biopharma (ABUS) at Hold

Dec 13, 2021 10:58 AM Arbutus Biopharma (ABUS) PT Raised to $10 at JMP Securities, Following Clinical Business Update

Dec 13, 2021 07:31 AM Arbutus Biopharma (ABUS) and Qilu Enter Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan

Dec 8, 2021 12:07 PM H.C. Wainwright Reiterates Buy Rating on Arbutus Biopharma (ABUS) Amid Progress on Pan-Coronavirus Treatment

Dec 7, 2021 07:56 AM Arbutus Biopharma (ABUS) issued U.S. patent 11,191,849 "Compositions and methods for delivering messenger RNA" - IP Hawk

Dec 7, 2021 07:31 AM Arbutus Biopharma (ABUS), X-Chem and Proteros Achieve First Milestone Under COVID-19 Discovery Research and License Agreement

Dec 3, 2021 03:53 AM Increasing unusual option volume: ARDX RRR BLU BKLN ABUS MFA

Dec 2, 2021 04:05 AM Increasing unusual put option volume: ABUS EWH SABR CNQ

Dec 1, 2021 11:59 AM Arbutus Biopharma (ABUS) Announces Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity

Dec 1, 2021 11:49 AM Arbutus Biopharma (ABUS) Pushes to Session Highs Following Patent Decision